Gore touts 1st commercial use of Tag thoracic stent graft

W.L. Gore & Associates said today its Tag conformable thoracic stent graft was used in its 1st commercial procedure after the system won CE Mark approval in the European Union last month. The procedure was performed by Dr. Giovanni Torsello and Dr. Martin Austermann of Munster, Germany’s St. Franziskus Hospital, the Flagstaff, Ariz.-based company said. “The enhanced control capabilities this new delivery system allows could reduce many common complications that can occur if the stent graft is not placed correctly during the TEVAR procedure. Secondary interventions can be traumatic for patients and costly to the provider. The innovative staged deployment feature of the Gore Active Control System provides a level of precision that has never existed in TEVAR. This level of control in combination with the long-term benefits of the stent graft is a significant advancement for the field,” Dr. Giovanni Torsello of Munster, Germany’s St. Franziskus Hospital said in a prepared statement. Gore’s thoracic endovascular aortic repair device is designed with a new delivery system to allow for controlled, staged deployment. The system is designed to improve accuracy, angulation and apposition for treating etiologies of the descending thoracic aorta including aneurysms, transections and acute and chronic Type B resections, the company said. “Since Gore pioneered the first TEVAR device in Europe two decades ago, we have welcomed feedback from our phys...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Stent Grafts Vascular W.L. Gore & Associates Source Type: news